Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Operating Income: 2020-2024

Historic Operating Income for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to -$145.6 million.

  • Tango Therapeutics' Operating Income rose 142.80% to $14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$110.3 million, marking a year-over-year increase of 21.02%. This contributed to the annual value of -$145.6 million for FY2024, which is 27.52% down from last year.
  • As of FY2024, Tango Therapeutics' Operating Income stood at -$145.6 million, which was down 27.52% from -$114.2 million recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' Operating Income registered a high of -$52.2 million during FY2020, and its lowest value of -$145.6 million during FY2024.
  • Over the past 3 years, Tango Therapeutics' median Operating Income value was -$114.2 million (recorded in 2023), while the average stood at -$123.6 million.
  • Data for Tango Therapeutics' Operating Income shows a maximum YoY tumbled of 90.88% (in 2022) over the last 5 years.
  • Tango Therapeutics' Operating Income (Yearly) stood at -$52.2 million in 2020, then declined by 11.48% to -$58.2 million in 2021, then crashed by 90.88% to -$111.1 million in 2022, then decreased by 2.79% to -$114.2 million in 2023, then decreased by 27.52% to -$145.6 million in 2024.